BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allegra A, Ettari R, Innao V, Bitto A. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma. Cells 2021;10:448. [PMID: 33672466 DOI: 10.3390/cells10020448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Apipongrat D, Roytrakul S, Prayongratana K, Charoenpitakchai M, Intharanut K, Laoruangroj C, Silpsamrit P, Nathalang O. Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma. PLoS One 2022;17:e0278464. [PMID: 36454786 DOI: 10.1371/journal.pone.0278464] [Reference Citation Analysis]
2 Clausse V, Zheng H, Amarasekara H, Kruhlak M, Appella DH. Thyclotides, tetrahydrofuran-modified peptide nucleic acids that efficiently penetrate cells and inhibit microRNA-21. Nucleic Acids Res 2022:gkac864. [PMID: 36215040 DOI: 10.1093/nar/gkac864] [Reference Citation Analysis]
3 Allegra A, Cancemi G, Mirabile G, Tonacci A, Musolino C, Gangemi S. Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma. Cancers 2022;14:4136. [DOI: 10.3390/cancers14174136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Allegra A, Cicero N, Tonacci A, Musolino C, Gangemi S. Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma. Cancers 2022;14:1700. [DOI: 10.3390/cancers14071700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
5 Xie L, Wei J, Gao Z, Huang H, Ju S, Wang X. Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma. Exp Cell Res 2022;:113113. [PMID: 35339472 DOI: 10.1016/j.yexcr.2022.113113] [Reference Citation Analysis]
6 Das S, Juliana N, Yazit NAA, Azmani S, Abu IF. Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment. Int J Mol Sci 2022;23:1649. [PMID: 35163567 DOI: 10.3390/ijms23031649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Allegra A, Tonacci A, Sciaccotta R, Genovese S, Musolino C, Pioggia G, Gangemi S. Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection. Cancers (Basel) 2022;14:606. [PMID: 35158874 DOI: 10.3390/cancers14030606] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
8 Allegra A, Di Gioacchino M, Tonacci A, Petrarca C, Musolino C, Gangemi S. Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies. Cells 2021;10:2865. [PMID: 34831088 DOI: 10.3390/cells10112865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Burgos-Ravanal R, Campos A, Díaz-Vesga MC, González MF, León D, Lobos-González L, Leyton L, Kogan MJ, Quest AFG. Extracellular Vesicles as Mediators of Cancer Disease and as Nanosystems in Theranostic Applications. Cancers (Basel) 2021;13:3324. [PMID: 34283059 DOI: 10.3390/cancers13133324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]